Targeting Inflammation in Eye Diseases with Iolyx Therapeutics’ CEO Elizabeth Jeffords

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Elizabeth Jeffords, CEO, Iolyx Therapeutics, which is developing targeted therapies to address inflammation in ocular disease. Elizabeth is a seasoned biotech leader with experience spanning company building, fundraising, clinical development, major product launches and a >$9 billion global P&L. Before Iolyx, she served as Chief Commercial & Strategy Officer at Alkahest and held leadership roles at Genentech and Roche. An angel investor with Portfolia, she serves on several boards, including the boards of Iolyx, Ashvattha and Biotechnology Innovation Organization (BIO). Elizabeth holds a Bachelor of Science (BS) in Biology & Management from Yale and a Masters of Business & Technology from UNSW, Australia, which she attended as a Fulbright Scholar. Tune in to learn more about addressing inflammation in ocular diseases such as dry eye disease and more. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured